Hematology
Conference Coverage
Need blood STAT? Call for a drone
BOSTON – Autonomous unmanned aerial vehicles bring blood to remote hospitals in Africa, but a U.S.-based system will need to overcome significant...
Feature
Tech-based cancer company raises access concerns
Oncologists say a new company that aims to link patients with cancer care and clinical trials through technology has both positives and negatives...
News
FDA approves DNA-based blood type test
This is the first molecular-based test for red blood cell types to report genotypes in its results.
From the Journals
Crizanlizumab relieves sickle cell crises across subgroups
The post hoc analysis of the SUSTAIN trial showed a significant decrease in painful vaso-occlusive crises.
Clinical Inquiries
What’s the best VTE treatment for patients with cancer?
EVIDENCE-BASED ANSWER: No head-to-head studies directly compare all the main treatments for venous thromboembolism (VTE) in cancer patients. Long-...
Applied Evidence
Strategies for caring for the well cancer survivor
Surveillance of existing cancer, management of treatment-related adverse effects, and screening for second cancers are key to the care you'll...
Conference Coverage
Antithrombotic strategy 1 year after stenting in AF patients leans toward oral anticoagulant alone
SAN DIEGO – A primary endpoint failed to show noninferiority of oral anticoagulants alone versus anticoagulants plus antiplatelet therapy, but a...
From the Journals
Coagulopathy outbreak underscores danger of synthetic cannabinoids
Four patients died after developing spontaneous intracranial bleeding.
Conference Coverage
Rivaroxaban bonus: Early unmasking of occult GI cancers
MUNICH – Secondary analysis of COMPASS trial hits pay dirt.
From the Journals
Hormonal contraceptive use linked to leukemia risk in offspring
Maternal use of hormonal contraceptives close to pregnancy is associated with a small increase in the risk of nonlymphoid leukemia in offspring....
Latest News
Caplacizumab approved in Europe to treat aTTP
The drug is under priority review by the U.S. Food and Drug Administration.